Avalo Therapeutics shares are trading higher after the company announced the LOTUS trial successfully met its primary endpoint at both doses studied. The company announced an offering.

Benzinga Newsdesk www.benzinga.com Positive 90.5%

Neg 0% Neu 0% Pos 90.5%

Comments

No comments yet. Be the first!